UK Members 
US Members 
“www.off-label.com is a brilliant and user-friendly solution to the impossible problem of tracking the vast, chaotic and expanding literature relevant to off-label drug use. Like other elegant solutions to challenging problems, it makes one wonder why no one thought of it sooner. The competitive advantage it offers subscribers makes it a must for those in big, small, and specialty pharma, biotech, as well as clinical practice.”
Daniel B Carr MD, MS, BS, FABM
Saltonstall Professor of Pain Research in the Department of Anesthesia
Tufts University School of Medicine
CEO Javelin Pharmaceuticals
"As the cost for new entity pharmaceutical development spirals, more companies are turning to drug-reprofiling as a lower risk approach to drug discovery. Off-label.com offers a low-cost solution to identify new uses for the existing pharmacopoeia - a way that is based on clinical validation. There are few ways that are lower risk than this!
Project Leader Drug Discovery
"In palliative care, up to a quarter of all prescriptions are for drugs given for 'off-label' (unlicensed) indications and/or via an unlicensed route - and the situation is probably the same in most other medical specialties. Yet, for marketing purposes, the Summary of Project Characteristics and the corresponding Patient Information are both strictly limited to the terms of the product license. The need for an authoritative, updating synopsis of indications for the off-label use of drugs is overwhelming."
"Medical knowledge and associated clinical experience are generally wider, sometimes far wider, that the 'strait-jacket' of the license. In my opinion, OFF-LABEL is a 'must' for all medical specialists and pharmacists. Its potential role in general professional training is also considerable, and will go a long way towards achieving the goal of 'evidence-based' prescribing."
Robert Twycross DM, FRCP, FRCR
Emeritus Clinical Reader in Palliative Medicine
Oxford University
Director, WHO Collaborating Centre for Palliative Care, Oxford
Academic Director, Oxford International Centre for Palliative Care
Director, palliativedrugs.com Ltd
"This new program (CDU) for capturing field discovery offers an entirely unique method of drug discovery. Narrative on novel observations constitutes a vast pool of innovation that for the first time will be reported at a central site.
Importantly, CDU also offers clinicians and scientists the novel opportunity to bring together serendipity....one of the best markers for science's greatest discoveries.... and experience within CDU's section on hypotheses. Furthermore, because the data used to generate the new hypotheses will be based upon existing clinical entities and data obtained in humans, this method offers unparalleled advantages compared to other drug discovery strategies"
Richard A Bond PhD.,
Dept of Pharmacological and Pharmaceutical Sciences,
University of Houston, College of Pharmacy